Canaccord Genuity analyst Kyle Mikson CFA has maintained their bullish stance on BDSX stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kyle Mikson CFA has given his Buy rating due to a combination of factors that highlight Biodesix’s improving fundamentals and attractive upside potential. He notes that the company’s preliminary fourth-quarter and full-year 2025 results significantly exceeded both his estimates and market expectations, with robust revenue growth driven by higher test volumes and better revenue per test. Importantly, Biodesix reached positive adjusted EBITDA in 4Q25 despite its relatively small revenue base, demonstrating meaningful operating leverage supported by high gross margins and disciplined operating expenses. Mikson also emphasizes that the company’s increased sales force and greater focus on the primary care channel are translating into stronger commercial execution and accelerating test adoption.
Furthermore, Mikson underscores that full-year revenue surpassed the top end of management’s guidance range, supported by solid performance in both Lung Diagnostics and Development Services. He views the company’s progress in reducing cash burn and modestly improving its cash position, even before at-the-market proceeds, as a positive signal for Biodesix’s financial health and path toward sustained profitability. In his view, the combination of renewed growth momentum, improving profitability metrics, and strategic sales expansion, along with a potentially value-creating pipeline and partnership opportunities, justifies a Buy rating. Given the meaningful upside to his $20 price target relative to the current share price, he considers Biodesix’s stock compelling at present levels.
According to TipRanks, Mikson CFA is a 4-star analyst with an average return of 4.4% and a 39.43% success rate. Mikson CFA covers the Healthcare sector, focusing on stocks such as Natera, GeneDx Holdings, and Tempus AI, Inc. Class A.
In another report released yesterday, Craig-Hallum also maintained a Buy rating on the stock with a $0.00 price target.